BPC-157 Safety and Clinical Evidence Explained

Somewhere in the last five years, self-injection stopped being strange. Millions of people now give themselves a weekly shot of semaglutide, better known by the brand names Ozempic or Wegovy, without a second thought. That normalization has quietly opened a door. If needles are fine for weight loss, the thinking goes, why not for a sore shoulder or a stubborn tendon? Enter the peptide trend, and the compound at its center, BPC-157.

A peptide, in plain terms, is a short chain of amino acids, the small molecules that link up to form proteins. Peptides show up in food, in supplements, and in medications; insulin and the GLP-1 drugs are peptides too (00:50). But when people online say "peptides," they almost never mean food or supplements. As Dr. Jordan Feigenbaum, founder of the coaching and education company Barbell Medicine, puts it on this episode of Sigma Nutrition Radio, "Peptides refer to a chemical structure that contains amino acids. It's usually a short chain of amino acids" (06:33). The peptides people are actually asking about are drugs, mostly unapproved ones, being taken by otherwise healthy people who want to recover faster, feel better, or simply live better through chemistry.

BPC-157 is the flagship example. It was developed in Croatia in the 1990s by a pharmaceutical lab and spent roughly fifteen years being tested only in animals and petri dishes before the first human trial ran in 2005 (11:01). That trial gave people BPC-157 enemas to treat ulcerative colitis, a gut condition; the results were never published in a journal, only presented as a conference abstract, and the improvement was not statistically significant (11:28). A couple of other trials started and either stopped early or never published results. Add it all up and the entire published human evidence base for BPC-157, the compound now recommended by fitness influencers for tendons, joints, and gut health, comes to about thirty people.

"For the entire human evidence base period, there's about 30 total human subjects that have been actually published." — Jordan Feigenbaum [11:47]

That is not a criticism of the compound itself. Feigenbaum is careful on this point: a lack of evidence does not mean a drug fails to work, and it does not mean people reporting good results are lying. It means nobody can say, with any confidence, what the drug's real safety profile is, or whether it does what people claim. "It doesn't mean that it's not [effective]," he says, "we just don't know" (12:14).

The uncertainty compounds once you look at how people actually obtain these substances. A prescription drug moves from a doctor to a pharmacy shelf. A less common drug might come from a compounding pharmacy, a specialized operation that mixes raw materials to order under the same quality standards as a regular pharmacy (18:41). Most peptide users skip both routes and buy from research chemical suppliers, companies that sell the same molecules labeled "not for human use." These sellers are not held to any standard for purity, contamination, or dose accuracy (19:23). Feigenbaum's phrase for the distance between that tier and a real pharmacy has stuck with listeners for a reason.

"There's a Grand Canyon-sized gap between compounding pharmacies and regular pharmacies and research chemical grade medications." — Jordan Feigenbaum [19:02]

He splits the overall risk of taking one of these drugs into two roughly equal halves (24:28). One half is sourcing: is the vial actually what the label says, at the dose it claims, free of contaminants? The peptide industry's own purity submissions to the Food and Drug Administration (FDA), the U.S. regulator, have been judged insufficient by the agency itself (25:09). The other half is pharmacology: even with perfect purity, what does the drug actually do inside the body, and what does it do over months or years? For most of these compounds, that second half remains a shrug.

What the FDA Vote Actually Changed

Some of the recent confusion traces back to a real regulatory event that got flattened into a rumor. A group of peptide drugs, including BPC-157, KPV, TB-500, MOTS-c, and Semax, sat on the FDA's so-called Category 2 list, meaning the agency judged there was insufficient data or a potential safety risk (28:35). Compounding pharmacies are legally barred from working with anything on that list. Earlier this year, the companies that had originally submitted these drugs for review withdrew their submissions, which triggered a fresh panel vote on whether to move them off Category 2. Six of the seven drugs were voted off (29:18). That does not mean compounding pharmacies can dispense them yet; another vote is scheduled for 2027. It certainly does not mean the FDA approved them the way it approves a blood pressure medication, a process that requires completed clinical trials in humans (27:12). Of the seven drugs on that panel's docket, none has published randomized controlled trial data for the conditions they are supposedly used for (50:24).

Why the Drug Companies Walked Away

A common explanation online for the lack of studies is that BPC-157 can't be patented because it occurs naturally, so no company has a financial reason to test it properly. Feigenbaum is skeptical. Many naturally occurring peptides, including several forms of insulin and the GLP-1 drugs, have been patented, and BPC-157 itself has been patented before (45:59). Patents aside, there are other legal ways to protect market exclusivity. His more uncomfortable question is why pharmaceutical companies, having already spent money developing these compounds, walked away after early-phase trials rather than push toward a payday. The likely answer, he suggests, is some mix of safety signals that showed up in testing and results that simply did not beat placebo (43:28).

He also points to an incentive problem that gets worse the more available these drugs become on the black market. If people can already get a compound cheaply and without a prescription, there is less commercial reason for anyone to fund the expensive trials that would settle the question for good (45:59). He is skeptical, too, of the argument that moving these drugs to safer, compounding-pharmacy channels is a pure harm-reduction win. A needle exchange program does not meaningfully grow the number of people using intravenous drugs; a telehealth company marketing peptides with real advertising budgets almost certainly would grow the user base (48:11). Making the product cleaner while the underlying question, does it work, does it harm, remains unanswered, is not obviously harm reduction. It may just be a bigger, cleaner-looking experiment on more people.

That experiment looks different depending on who is running it on themselves. Feigenbaum draws a real distinction between a healthy person chasing marginal gains and an elite athlete facing a career-ending injury with no good options; higher risk tolerance makes more sense in the second case (37:40). But he is wary of the reasoning that gets used to wave away risk in general, especially the observation that young lifters who take all sorts of experimental compounds mostly seem fine.

"It's really hard to kill 20, 20-somethings." — Jordan Feigenbaum [38:51]

Healthy young people with no other medications and no comorbidities are exactly the population least likely to reveal a drug's downside. The person more likely to run into trouble, he says, is someone in their forties or fifties with existing conditions and prescriptions, who hears about peptides from a trainer or an influencer and adds one more unknown variable to an already complicated picture (39:17). Blood work, he adds, is not built to catch the specific side effects nobody has looked for yet (42:27).

None of this makes Feigenbaum an anti-peptide crusader; he is careful to distance himself from that camp too, and from the mockery some skeptics aim at anyone curious about these drugs. His actual position is smaller and harder to sell online: we do not know, we would like to know, and pretending otherwise in either direction is a poor way to get informed consent (33:59).

"I'm not trying to instill additional fear that's unnecessary. I'm more just trying to be honest about where my perspective lies." — Jordan Feigenbaum [53:05]

The conversation ends somewhere unexpectedly warm. Feigenbaum and podcast host Danny Lennon touch briefly on his new book about testosterone, which argues that male testosterone levels have not actually fallen much over thirty years once you account for changes in how labs test for it (54:25). Then, asked for one daily habit worth adopting, Feigenbaum skips supplements entirely and suggests sending one person a day a message about something admired in them (55:39). It is a small, almost sentimental close to an episode otherwise built on refusing to overstate what science knows. The two ideas share a spine: certainty is worth waiting for, and in its absence, honesty about the gap is the only responsible thing on offer.